Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Exelixis, Inc. (NasdaqNM:EXEL)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
Recent Events
Aug  8Earnings Announcement
Location
170 Harbor Way, P.O. Box 511
South San Francisco, CA 94083
Phone: (650) 837-7000
Fax: (650) 825-2205
Email: info@exelixis.com
Employees (last reported count): 357
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 41%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · 6 insider sells; 494.0K shares
  (2.4% of insider shares)
·Institutional: 47% (79% of float)
(156 institutions)
·Net Inst. Buying: 3.07M shares (+11.82%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Exelixis, Inc. is a biotechnology company focused on the discovery and validation of novel targets for several major human diseases, and on the discovery of potential new drug therapies, specifically for cancer and other proliferative diseases. The Company is focused on the life sciences industries and development of proprietary drugs, through its experience in comparative genomics and model system genetics. The Company also develops proprietary genetic, biochemical and cell-based assays for use in screening for potential targets, proteins and products.
More from Market Guide: Expanded Business Description

Financial Summary
Exelixis, Inc. is a provider of comparative genomics and model system genetics services, allowing for the identification and validation of novel screening targets and proteins and their function for the pharmaceutical, diagnostic and other industries. For the six months ended 6/30/01, total revenues rose 41% to $16.3 million. Net loss rose 99% to $36.4 million. Results reflect additional contract revenues from existing collaborations, offset by increased staffing.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Stelios Papadopoulos, Ph.D., 52
Chairman
--  --  
George Scangos, Ph.D., 52
Pres, CEO, Director
$672K$680K
Glen Sato, 42
CFO, VP of Legal Affairs and Sec.
240K169K
Geoffrey Duyk, M.D., Ph.D., 41
Director, CSO
443K240K
Lloyd Kunimoto, 47
Sr. VP, Bus. Devel.
290K240K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:EXELAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$6.00 
Recent Price$16.78 
52-Week High
on 5-Sep-2000
$47.75 
Daily Volume (3-month avg)332.6K
Daily Volume (10-day avg)429.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-63.4%
52-Week Change
relative to S&P500
-50.9%
Share-Related Items
Market Capitalization$824.9M
Shares Outstanding49.2M
Float29.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.12 
Earnings (ttm)-$2.16 
Earnings (mrq)-$0.52 
Sales (ttm)$0.68 
Cash (mrq)$2.50 
Valuation Ratios
Price/Book (mrq)5.37 
Price/EarningsN/A 
Price/Sales (ttm)24.72 
Income Statements
Sales (ttm)$29.5M
EBITDA (ttm)-$97.8M
Income available to common (ttm)-$93.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-50.27%
Return on Equity (ttm)-67.07%
Financial Strength
Current Ratio (mrq)4.75 
Debt/Equity (mrq)0.32 
Total Cash (mrq)$123.1M
Short Interest
As of 8-Aug-2001
Shares Short1.73M
Percent of Float6.0%
Shares Short
(Prior Month)
1.43M
Short Ratio6.17 
Daily Volume281.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.